Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
Authors
Keywords
-
Journal
BRITISH JOURNAL OF OPHTHALMOLOGY
Volume 98, Issue 9, Pages 1192-1196
Publisher
BMJ
Online
2014-04-12
DOI
10.1136/bjophthalmol-2013-304556
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
- (2013) Usha Chakravarthy et al. LANCET
- Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
- (2013) Brandon G. Busbee et al. OPHTHALMOLOGY
- Age-Related Macular Degeneration, Anti-VEGF Therapy, and Ophthalmic Imaging
- (2013) Dennis P. Han JAMA Ophthalmology
- Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration
- (2012) Irmela Mantel et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
- (2012) Daniel F. Martin et al. OPHTHALMOLOGY
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study
- (2011) Frank G. Holz et al. OPHTHALMOLOGY
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2
- (2010) Prema Abraham et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular DegenerationClinical and Economic Impact
- (2010) Omesh P. Gupta et al. OPHTHALMOLOGY
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
- (2010) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED
- (2010) Hassiba Oubraham et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
- (2009) Geeta A. Lalwani et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical Setting
- (2009) Salomon Y. Cohen et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration
- (2009) David S. Boyer et al. OPHTHALMOLOGY
- Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration
- (2009) Hajir Dadgostar et al. OPHTHALMOLOGY
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
- (2008) Carl D. Regillo et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Early Clinical Experience with Ranibizumab for Occult and Minimally Classic Neovascular Membranes in Age-Related Macular Degeneration
- (2008) Irmela Mantel et al. OPHTHALMOLOGICA
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
- (2008) David M. Brown et al. OPHTHALMOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation